JP2002528064A - 硬化症の治療における抗真菌剤の使用 - Google Patents

硬化症の治療における抗真菌剤の使用

Info

Publication number
JP2002528064A
JP2002528064A JP2000578012A JP2000578012A JP2002528064A JP 2002528064 A JP2002528064 A JP 2002528064A JP 2000578012 A JP2000578012 A JP 2000578012A JP 2000578012 A JP2000578012 A JP 2000578012A JP 2002528064 A JP2002528064 A JP 2002528064A
Authority
JP
Japan
Prior art keywords
fungus
genus
rodhotorula
fungi
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000578012A
Other languages
English (en)
Japanese (ja)
Inventor
アントノフ，ルマン
Original Assignee
カンディダ・メディカル・ベー・ヴェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カンディダ・メディカル・ベー・ヴェー filed Critical カンディダ・メディカル・ベー・ヴェー
Publication of JP2002528064A publication Critical patent/JP2002528064A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2000578012A 1998-10-27 1999-10-27 硬化症の治療における抗真菌剤の使用 Pending JP2002528064A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9802302 1998-02-20
PCT/FR1998/002302 WO2000024402A1 (fr) 1998-10-27 1998-10-27 Utilisation d'antifongiques dans le traitement des scleroses
PCT/FR1999/002617 WO2000024403A1 (fr) 1998-10-27 1999-10-27 Utilisation d'antifongiques dans le traitement des scleroses

Publications (1)

Publication Number Publication Date
JP2002528064A true JP2002528064A (ja) 2002-09-03

Family

ID=9523370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000578012A Pending JP2002528064A (ja) 1998-10-27 1999-10-27 硬化症の治療における抗真菌剤の使用

Country Status (8)

Country Link
EP (1) EP1124560A1 (pt)
JP (1) JP2002528064A (pt)
CN (1) CN1328466A (pt)
AU (2) AU1036999A (pt)
BR (1) BR9914792A (pt)
CA (1) CA2348160A1 (pt)
IL (1) IL142641A0 (pt)
WO (2) WO2000024402A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
CN110269939A (zh) * 2019-03-12 2019-09-24 武汉愔紫生物科技有限公司 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法
CN110343650B (zh) * 2019-05-28 2020-12-29 浙江工业大学 一种产两性霉素b的重组结节链霉菌及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE753078A (fr) * 1969-07-07 1971-01-07 Schmid Inc Julius Compositions de traitement de l'hyperlipemie
US4289757A (en) * 1978-02-28 1981-09-15 The Upjohn Company Method for treating inflammation
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
GB2290707A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of Amphotericin B
GB2290709A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of nystatin

Also Published As

Publication number Publication date
CA2348160A1 (fr) 2000-05-04
AU1036999A (en) 2000-05-15
EP1124560A1 (fr) 2001-08-22
AU6347199A (en) 2000-05-15
WO2000024403A1 (fr) 2000-05-04
BR9914792A (pt) 2001-11-27
WO2000024402A1 (fr) 2000-05-04
IL142641A0 (en) 2002-03-10
CN1328466A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
Singh et al. Infections due to dematiaceous fungi in organ transplant recipients: case report and review
Shahi et al. Microbially synthesized bioactive nanoparticles and their formulation active against human pathogenic fungi
US20220331386A1 (en) Anti-microbial seaweed extracts, compositions and uses thereof
JP2002526407A (ja) フルボ酸、および種々の状態の処置におけるその使用
JP2002528064A (ja) 硬化症の治療における抗真菌剤の使用
HEINEMAN et al. Chlamydospores and Dimorphism in Candida albicans Endocarditis: observations in a fatal superinfection during treatment of Staphylococcus Endocarditis
Wolinsky Chemotherapy and pathology of experimental photochromogenic mycobacterial infections
KNIGHT The activity of various topical griseofulvin preparations and the appearance of oral griseofulvin in the stratum corneum
HU186767B (en) Process for producing compositions for treating dermatologicalanomalys
RU2613708C2 (ru) Способ лечения угревой болезни
EA013519B1 (ru) Противобактериальный или педикулоцидный препарат, содержащий аллицин
Smyth Fungal infection of the post-operative mastoid cavity
EP1881838B1 (en) Antitumor agent on the base of bcg vaccine, method for its preparation and its use
RU2749481C1 (ru) Способ терапии поверхностных микозов
US5462929A (en) Treatment of psoriasis by administration of 4-carbamoyl-1-β-D-ribofuranosylimidszolium-5-oleate
US10398664B2 (en) Methods of diagnosing and treating infected implants
DESAI et al. Effect of Griseofulvin on Trichophyton Rubrum and Trichophyton Violaceum Infections: Clinicomycological Correlation of the Mode of Action in Tissues
US10195216B1 (en) Antimicrobial activity and oil compositions of Costus speciosus (KOEN)
Chadwick et al. Therapeutic experience with netilmicin.
TWI680756B (zh) 使用2,4-二甲氧基-6-甲基苯-1,3-二醇來防止和/或抑制葡萄球菌屬物種的生長以及生物膜形成
Mercantini et al. Macroscopic and microscopic characteristics of an African Blastomyces dermatitidis strain: Makroskopische und mikroskopische Merkmale eines afrikanischen Blastomyces dermatitidis‐Stammes
CA2448045A1 (fr) Identification de champignons parasites de l'organisme, et leur traitement
CN115300528A (zh) 一种抑制金黄色葡萄球菌的大硝软膏及其制备方法和应用
WO2020033677A1 (en) Methods of diagnosing and treating infected implants
CN115715799A (zh) 用于预防或治疗真菌感染的组合物及其制剂、制备方法和应用